Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Expands Antibody Collaboration With Xoma

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal builds on May agreement to discover and develop therapeutic monoclonal antibodies.

You may also be interested in...



Xoma Launches Phase I Trial Of Monoclonal Antibody Diabetes Therapy

Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.

Xoma Launches Phase I Trial Of Monoclonal Antibody Diabetes Therapy

Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.

Takeda Expands Antibody Collaboration With Xoma

Agreement now could earn California company $230 million before royalties for identifying therapeutic antibodies that target cancer.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel